Faricimab
- Generic Name
- Faricimab
- Brand Names
- Vabysmo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1607793-29-2
- Unique Ingredient Identifier
- QC4F7FKK7I
- Background
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV). Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as...
- Indication
Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Associated Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD), Visual Impairment
- Associated Therapies
- -
European Medicines Agency approves faricimab (Vabysmo) 6.0 mg single-dose prefilled syringe
Roche announced EMA approval for faricimab (Vabysmo) in a 6.0 mg single-dose prefilled syringe for neovascular AMD, DME, and macular edema following RVO. The PFS offers a convenient administration method, potentially reducing treatment burden for patients and specialists.
Eylea 8-milligram meets primary endpoint in Phase III study
Bayer's Eylea showed non-inferior visual acuity improvement in a phase III trial with 8 mg every 8 weeks vs. 2 mg every 4 weeks for retinal vein occlusion. This longer interval makes Eylea more attractive for patients needing eye injections, competing with Roche's Vabysmo.
Vabysmo prefilled syringe receives European approval
The European Medicines Agency approved the Vabysmo 6 mg prefilled syringe for wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.
Roche Vabysmo prefilled syringe approved in EU for three retinal conditions that can cause...
Roche announced the European Medicines Agency approved Vabysmo (faricimab) 6.0 mg prefilled syringe for treating neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. Vabysmo, a bispecific antibody, targets Ang-2 and VEGF-A pathways to stabilize blood vessels, reducing vision loss. The prefilled syringe offers a convenient administration method, easing treatment burden for patients and specialists.
Roche Vabysmo PFS approved in EU for three retinal conditions
Roche announced EMA approval of Vabysmo 6.0 mg PFS for treating nAMD, DME, and macular edema following RVO, affecting over 9M people in the EU. This simplifies administration, potentially reducing treatment burden for patients and specialists.
EMA approves Roche's Vabysmo prefilled syringe for three retinal conditions that can cause
Roche's Vabysmo (faricimab) 6.0 mg prefilled syringe approved by the European Medicines Agency for treating neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. Vabysmo, the first bispecific antibody for the eye, targets Ang-2 and VEGF-A pathways to stabilise blood vessels, reducing vision loss. It is available in over 100 countries and offers a convenient administration method.
Innovative biologic prefilled syringe approved in EU
EMA approves Roche’s Vabysmo prefilled syringe, the EU’s first bispecific antibody PFS for treating retinal conditions causing vision loss, including nAMD, DME, and RVO. The biologic inhibits Ang-2 and VEGF-A pathways to stabilise blood vessels in the eye, offering a convenient treatment option for patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath